Literature DB >> 6423129

Splint renal function after captopril in unilateral renal artery stenosis.

G J Wenting, H L Tan-Tjiong, F H Derkx, J H de Bruyn, A J Man in't Veld, M A Schalekamp.   

Abstract

The renal extraction ratios of 131I-sodium iodohippurate (131I-Hippuran) and 125I-thalamate were greatly reduced on the affected side by 50 mg captopril in seven out of 14 patients with unilateral renal artery stenosis. With long term captopril 150 mg daily the uptake of 99mTc-diethylenetriaminepenta-acetic acid by the affected kidney, which was determined by scintillation camera renography, became almost zero in these seven patients, indicating severe reduction of the glomerular filtration rate. Function of the affected kidney returned on discontinuing treatment. The reduced extraction of sodium iodohippurate probably reflected a shortened plasma transit time through the kidney due to intrarenal vasodilatation. The reduced extraction of thalamate reflected a low filtration fraction, suggesting that the vasodilatation was, at least in part, at the level of the postglomerular arterioles. Captopril had little effect on the contralateral kidney and on the kidneys of 17 patients with essential hypertension, and serum creatinine concentrations showed minor changes. Radioisotope renography should be performed after beginning captopril treatment in patients with renal artery stenosis. This is also recommended for patients given captopril as a third line drug when renal artery stenosis has not been excluded. Hypertension is these patients is often severe and difficult to control. Renal artery disease is not rare in this difficult group and finding seriously impaired renal function on one side during captopril treatment may be diagnostic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423129      PMCID: PMC1441698          DOI: 10.1136/bmj.288.6421.886

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  24 in total

1.  Reversible renal failure during treatment with captopril.

Authors:  P R Farrow; R Wilkinson
Journal:  Br Med J       Date:  1979-06-23

2.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

3.  Control of glomerular filtration rate by renin-angiotensin system.

Authors:  J E Hall; A C Guyton; T E Jackson; T G Coleman; T E Lohmeier; N C Trippodo
Journal:  Am J Physiol       Date:  1977-11

4.  Hemodynamics of arterial stenoses at elevated flow rates.

Authors:  D F Young; N R Cholvin; R L Kirkeeide; A C Roth
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

5.  Reversible renal failure during treatment with captopril.

Authors:  P Collste; K Haglund; G Lundgren; G Magnusson; J Ostman
Journal:  Br Med J       Date:  1979-09-08

6.  Influence of cortical plasma transit-time on p-aminohippurate extraction during induced renal vasodilatation in anaesthetized dogs.

Authors:  M T Velasquez; A V Notargiacomo; J N Cohn
Journal:  Clin Sci       Date:  1972-09       Impact factor: 6.124

7.  Dynamics of glomerular ultrafiltration in the rat. II. Plasma-flow dependence of GFR.

Authors:  B M Brenner; J L Troy; T M Daugharty; W M Deen; C R Robertson
Journal:  Am J Physiol       Date:  1972-11

8.  Haemodynamic characteristics of low-renin hypertension.

Authors:  M A Schalekamp; W H Birkenhäger; G A Zaal; G Kolsters
Journal:  Clin Sci Mol Med       Date:  1977-04

9.  99mTc-DTPA scintillation-camera renography: a new method for estimation of single-kidney function.

Authors:  S P Nielsen; M L Moller; J Trap-Jensen
Journal:  J Nucl Med       Date:  1977-02       Impact factor: 10.057

10.  Are mineralocorticoid receptors present in human renal adenocarcinoma?

Authors:  M E Rafestin-Oblin; C Roth-Meyer; M Claire; A Michaud; E Baviera; J M Brisset; P Corvol
Journal:  Clin Sci (Lond)       Date:  1979-11       Impact factor: 6.124

View more
  16 in total

Review 1.  An evidence-based approach to diagnosing renovascular hypertension.

Authors:  M J Bloch
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 2.  Quantification of renal haemodynamics with radionuclides.

Authors:  A M Peters
Journal:  Eur J Nucl Med       Date:  1991

3.  Fetal and infantile hypertension caused by unilateral renal arterial disease.

Authors:  D I Wilson; R E Appleton; M G Coulthard; R E Lee; C Wren; H H Bain
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

Review 4.  Nuclear medicine to image applied pathophysiology: evaluation of reserves by emission computerized tomography.

Authors:  U Buell; H Schicha
Journal:  Eur J Nucl Med       Date:  1990

Review 5.  Clinical applications of nuclear medicine.

Authors:  G Ciofetta; I Gordon; A Piepsz
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

Review 6.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 7.  The kinetic basis of glomerular filtration rate measurement and new concepts of indexation to body size.

Authors:  A M Peters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-31       Impact factor: 9.236

Review 8.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 9.  Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.

Authors:  A L Kamper
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 10.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.